# **Thrombogenesis in antipsychotics**

Published: 14-02-2012 Last updated: 30-04-2024

Is there an increase in markers of trombogenese (platelet activation, d-dimeer, von willebrandfactor, OPG) in elderly users of antipsychotics six to ten days after the start in comparison to the same markers before start of the antipsychotic...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Coagulopathies and bleeding diatheses (excl thrombocytopenic)
Study type	Observational invasive

### **Summary**

### ID

NL-OMON37658

**Source** ToetsingOnline

**Brief title** Thrombogenesis in antipsychotics

### Condition

- Coagulopathies and bleeding diatheses (excl thrombocytopenic)
- Central nervous system vascular disorders
- Psychiatric and behavioural symptoms NEC

**Synonym** use of antipsychotics, use of neuroleptics

# Research involving

Human

### **Sponsors and support**

**Primary sponsor:** Universitair Medisch Centrum Utrecht **Source(s) of monetary or material Support:** Ministerie van OC&W,ZonMW (financiering via Ephor; expertisecentrum pharmacotherapie bij ouderen)

### Intervention

Keyword: Antipsychotic agents, Biological markers/blood, Elderly, Thrombogenesis

#### **Outcome measures**

#### **Primary outcome**

- 1. Platelet activation tests
- 2. D-dimeer
- 3. Von Willebrand Factor
- 4. Osteoprotegerine (OPG)

#### Secondary outcome

Age (in years)

Sexe (male/female)

Comorbidity

In case of dementia, also the seriousness of the dementia according to the

Clinical Dementia Rating scale

In case of Parkinson(ism), also the seriousness according to the Hoehn en Yahr

criteria

Medication

Type antipsychotic

Dosage of the antipsychotic

Indication of prescribing the antipsychotic medication

The medical record will be used as the source for the secundairy study

parameters

# **Study description**

#### **Background summary**

The food and drug administration notified in 2005 that antipsychotics are associated with an increased risk of mortality in elderly patients. This fact can not be explained by more coronary events, but there seem to be more cerebrovascular events and thrombo-embolic events. A possible explaination is an increase in thrombogenesis factors in blood. In elderly users of antipsychotics there is no answer to the question what the mechanism is behind the increased (cerebro) vascular mortality.

#### **Study objective**

Is there an increase in markers of trombogenese (platelet activation, d-dimeer, von willebrandfactor, OPG) in elderly users of antipsychotics six to ten days after the start in comparison to the same markers before start of the antipsychotic medication?

#### Study design

**Prospective study** 

#### Study burden and risks

Two times vena puncture The burden for the patient is low, there are no risks for the participants

### Contacts

Public Universitair Medisch Centrum Utrecht

Heidelberglaan 100 Utrecht 3508 GA NL **Scientific** Universitair Medisch Centrum Utrecht

Heidelberglaan 100 Utrecht 3508 GA NL

# **Trial sites**

### **Listed location countries**

Netherlands

## **Eligibility criteria**

Age Adults (18-64 years) Elderly (65 years and older)

#### **Inclusion criteria**

Age above 65 years start of an antipsychotic drug informed consent

#### **Exclusion criteria**

history of venous tromboemoblism or deep venous thrombosis malignancy with treatment in the last 6 months or palliative treatment bedridden or immobilisation for more than tree days operation in the four previous weeks delirium or acute psychosis, as indication of use of antipsychotic drug use of an antipsychotic in the 6 months previous to the start of the studie other changes in medication within the 10 days of observation

### Study design

#### Design

Study type: Observational invasive		
Masking:	Open (masking not used)	
Control:	Uncontrolled	
Primary purpose:	Treatment	

### Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	24-01-2013
Enrollment:	20
Туре:	Actual

# **Ethics review**

Approved WMO	
Date:	14-02-2012
Application type:	First submission
Review commission:	METC Universitair Medisch Centrum Utrecht (Utrecht)
Approved WMO	
Date:	05-09-2012
Application type:	Amendment

# **Study registrations**

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register CCMO **ID** NL38164.041.11